title: In-vitro anticancer and antimicrobial activities of PLGA/silver nanofiber composites prepared by electrospinning.
abstract: In the present work, a series of 0, 1 and 7 wt% silver nano-particles (Ag NPs) incorporated poly lactic-co-glycolic acid (PLGA) nano-fibers were synthesized by the electrospinning process. The PLGA/Ag nano-fibers sheets were characterized using SEM, TEM and DSC analyses. The three synthesized PLGA/silver nano-fiber composites were screened for anticancer activity against liver cancer cell line using MTT and LDH assays. The anticancer activity of PLGA nano-fibers showed a remarkable improvement due to increasing the concentration of the Ag NPs. In addition to the given result, PLGA nano-fibers did not show any cytotoxic effect. However, PLGA nano-fibers that contain 1 % nano silver showed anticancer activity of 8.8 %, through increasing the concentration of the nano silver to 7 % onto PLGA nano-fibers, the anticancer activity was enhanced to a 67.6 %. Furthermore, the antibacterial activities of these three nano-fibers, against the five bacteria strains namely; E.coli o157:H7 ATCC 51659, Staphylococcus aureus ATCC 13565, Bacillus cereus EMCC 1080, Listeria monocytogenes EMCC 1875 and Salmonella typhimurium ATCC25566 using the disc diffusion method, were evaluated. Sample with an enhanced inhibitory effect was PLGA/Ag NPs (7 %) which inhibited all strains (inhibition zone diameter 10 mm); PLGA/Ag NPs (1 %) sample inhibited only one strain (B. cereus) with zone diameter 8 mm. The PLGA nano-fiber sample has not shown any antimicrobial activity. Based on the anticancer as well as the antimicrobial results in this study, it can be postulated that: PLGA nanofibers containing 7 % nano silver are suitable as anticancer- and antibiotic-drug delivery systems, as they will increase the anticancer as well as the antibiotic drug potency without cytotoxicity effect on the normal cells. These findings also suggest that Ag NPs, of the size (5-10 nm) evaluated in the present study, are appropriate for therapeutic application from a safety standpoint.
authors.affiliation: Department of Botany and Microbiology, College of Science, King Saud University, Riyadh, Saudi Arabia.
authors.forename: Fahad N
authors.initials: FN
authors.lastname: Almajhdi
authors.forename: H
authors.initials: H
authors.lastname: Fouad
authors.forename: Khalil Abdelrazek
authors.initials: KA
authors.lastname: Khalil
authors.forename: Hanem M
authors.initials: HM
authors.lastname: Awad
authors.forename: Sahar H S
authors.initials: SH
authors.lastname: Mohamed
authors.forename: T
authors.initials: T
authors.lastname: Elsarnagawy
authors.forename: Ahmed M
authors.initials: AM
authors.lastname: Albarrag
authors.forename: Fawzi F
authors.initials: FF
authors.lastname: Al-Jassir
authors.forename: Hany S
authors.initials: HS
authors.lastname: Abdo
mesh_terms: D000890:Anti-Infective Agents / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001672:Biocompatible Materials / Q000737:chemistry*; D002460:Cell Line; D016503:Drug Delivery Systems; D055664:Electrochemical Techniques; D056945:Hep G2 Cells; D006801:Humans; D019344:Lactic Acid / Q000737:chemistry; D008113:Liver Neoplasms / Q000188:drug therapy; D008422:Materials Testing; D053768:Metal Nanoparticles / Q000737:chemistry / Q000648:ultrastructure; D008826:Microbial Sensitivity Tests; D008855:Microscopy, Electron, Scanning; D053761:Nanocomposites / Q000737:chemistry / Q000648:ultrastructure; D057139:Nanofibers / Q000737:chemistry / Q000648:ultrastructure; D011100:Polyglycolic Acid / Q000737:chemistry; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D012834:Silver / Q000008:administration & dosage*
chemical_list: D000890:Anti-Infective Agents; D000970:Antineoplastic Agents; D001672:Biocompatible Materials; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D012834:Silver